Takeda Pharmaceutical Company Limited (NYSE:TAK – Get a rating) saw a sharp drop in short-term interest rates during October. As of October 31, there was short interest totaling 3,990,000 shares, down 36.9% from the total of 6,320,000 shares as of October 15. Based on an average daily trading volume of 2,930,000 shares, the days-to-cover ratio is currently 1.4 days. Approximately 0.1% of the company’s shares are sold short.
Analyst upgrades and downgrades
Several equity research analysts have recently released reports on the company. Jefferies Financial Group downgraded Takeda Pharmaceutical from a “buy” rating to a “hold” rating in a Friday, July 29 research report. Cowen upgraded Takeda Pharmaceutical from a “market performance” rating to an “outperform” rating and raised its price target for the company from $21.00 to $24.00 in a Tuesday 19 research report. July. Finally, Cowen upgraded Takeda Pharmaceutical from a “market performance” rating to an “outperform” rating in a Tuesday, July 19 research report.
Institutional investors weigh in on Takeda Pharmaceutical
Several large investors have recently increased or reduced their stake in the stock. Herold Advisors Inc. acquired a new position in shares of Takeda Pharmaceutical during the first quarter worth $29,000. Ronald Blue Trust Inc. acquired a new position in shares of Takeda Pharmaceutical in Q2 worth $34,000. Allworth Financial LP increased its position in Takeda Pharmaceutical by 435.6% during the third quarter. Allworth Financial LP now owns 2,871 shares of the company worth $37,000 after acquiring an additional 2,335 shares during the period. Northwestern Mutual Wealth Management Co. increased its position in Takeda Pharmaceutical by 217.8% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 2,730 shares of the company worth $39,000 after acquiring 1,871 additional shares during the period. Finally, Addison Advisors LLC acquired a new stake in Takeda Pharmaceutical during Q1 worth approximately $48,000. 1.96% of the shares are held by institutional investors and hedge funds.
Takeda Pharmaceutical price performance
Shares of NYSE TAK opened at $13.84 on Friday. Takeda Pharmaceutical has a 1-year low of $12.28 and a 1-year high of $15.36. The company has a debt ratio of 0.62, a current ratio of 1.15 and a quick ratio of 0.75. The company’s fifty-day moving average price is $13.14 and its two-hundred-day moving average price is $13.80. The company has a market capitalization of $42.91 billion, a PE ratio of 25.63, a P/E/G ratio of 0.59 and a beta of 0.68.
Takeda Pharmaceutical (NYSE:TAK – Get a rating) last released its results on Thursday, October 27. The company reported earnings per share of $0.52 for the quarter. Takeda Pharmaceutical had a return on equity of 12.76% and a net margin of 5.60%. The company posted revenue of $7.26 billion for the quarter. On average, research analysts expect Takeda Pharmaceutical to post EPS of 2.1 for the current year.
Takeda Pharmaceutical Company Profile
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing and licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, the rest of Asia and internationally. It offers pharmaceutical products in the fields of gastroenterology, rare diseases, plasma-derived therapies, oncology and neurosciences.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Before you consider Takeda Pharmaceutical, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market spreads…and Takeda Pharmaceutical was not on the list.
Although Takeda Pharmaceutical currently has a “moderate buy” rating among analysts, top-rated analysts believe these five stocks are better buys.